Keywords: kosan, 17-aag, gets, orphan, drug, status, cml

Kosan's 17-AAG gets Orphan Drug status for CML from FDA

Article | 01 November 2004

Kosan Biosciences says its anticancer drug 17-allylamino-17-demethoxy-geldanamycin has been allocated Orphan Drug status for the treatment of chronic myelogenous ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Gleevec

Imatinib Mesylate

Go to drug listing